Glucagonoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glucagonoma}} | {{Glucagonoma}} | ||
{{CMG}};{{AE}}{{PSD}} | {{CMG}}; {{AE}} {{PSD}} | ||
==Overview== | ==Overview== | ||
The [[incidence]] of glucagonoma is approximately 0.0005 per 100,000 individuals worldwide. | The [[incidence]] of glucagonoma is approximately 0.0005 per 100,000 individuals worldwide. Glucagonoma affects men and women equally. The median age of diagnosis is the fifth decade. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
=== Incidence === | === Incidence === | ||
* Annual [[incidence]] is 0.01 to 0.1 new cases per 100,000.<ref name="pmid22261919">{{cite journal| author=Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P et al.| title=ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. | journal=Neuroendocrinology | year= 2012 | volume= 95 | issue= 2 | pages= 98-119 | pmid=22261919 | doi=10.1159/000335591 | pmc=3701449 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22261919 }}</ref> | * Annual [[incidence]] is 0.01 to 0.1 new cases per 100,000.<ref name="pmid22261919">{{cite journal| author=Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P et al.| title=ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. | journal=Neuroendocrinology | year= 2012 | volume= 95 | issue= 2 | pages= 98-119 | pmid=22261919 | doi=10.1159/000335591 | pmc=3701449 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22261919 }}</ref> | ||
Revision as of 14:26, 17 November 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucagonoma epidemiology and demographics |
|
Risk calculators and risk factors for Glucagonoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
The incidence of glucagonoma is approximately 0.0005 per 100,000 individuals worldwide. Glucagonoma affects men and women equally. The median age of diagnosis is the fifth decade.
Epidemiology and Demographics
Incidence
- Annual incidence is 0.01 to 0.1 new cases per 100,000.[1]
- Most glucagonomas are sporadic but up to 20 percent may be associated with the multiple endocrine neoplasia syndrome type 1. Glucagonomas occur in only 3 percent of MEN1 patients.[2][3]
Age
- Patients typically present in their fifth decade with lesions mainly located in the tail of the pancreas, whereas patients with MEN I present at the younger age of 33 y.[4][5]
Gender
- Glucagonoma affects men and women equally.
References
- ↑ Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
- ↑ Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D; et al. (2004). "Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry". Gastroenterol Clin Biol. 28 (11): 1075–81. PMID 15657529.
- ↑ Rajesh V. Thakker, Paul J. Newey, Gerard V. Walls, John Bilezikian, Henning Dralle, Peter R. Ebeling, Shlomo Melmed, Akihiro Sakurai, Francesco Tonelli & Maria Luisa Brandi (2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". The Journal of clinical endocrinology and metabolism. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327. Unknown parameter
|month=ignored (help) - ↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.
- ↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.